Tod Harper
6PUBLICATIONS
7CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Jan 21, 2026
An Industry Perspective on Key Considerations for the ICH S13 Guidance: Nonclinical Safety Evaluations of Oligonucleotide-Based Therapeutics.Jennifer D Sisler, Patrik Andersson, Alan Brown
|Sep 03, 2025
Use of a Transgenic Human PNPLA3I148M Knock-in Mouse for Translational Safety Evaluations of siRNA Therapeutics.Ben Brooks, Artem Shkumatov, Jackson Kalanzi
|Feb 06, 2025
Assessing Hybridization-Dependent Off-Target Risk for Therapeutic Oligonucleotides: Updated Industry Recommendations.Patrik Andersson, Sebastien A Burel, Heather Estrella
|Jan 23, 2025
Opportunities for More Tailored Approaches to Genotoxicity Testing and Carcinogenicity Strategy for Oligonucleotide Therapeutics: Outcome of an Industry Survey.Joel D Parry, Tod A Harper, Patrik Andersson
|Feb 16, 2024
Scientific Review of the Proarrhythmic Risks of Oligonucleotide Therapeutics: Are Dedicated ICH S7B/E14 Studies Needed for Low-Risk Modalities?Yusheng Qu, Kim A Henderson, Tod A Harper
|May 18, 2022
Characterization of an Anti-CD70 Half-Life Extended Bispecific T-Cell Engager (HLE-BiTE) and Associated On-Target Toxicity in Cynomolgus Monkeys.Tod Harper, Amy Sharma, Sarav Kaliyaperumal
Pageof 1
